Axiom Investors’s Tandem Diabetes Care TNDM Stock Holding History

Axiom Investors’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-37,440	Closed	-$2.21M	–	129
2019 Q3	$2.21M	Sell	37,440 -33,221	-47%	-$2.12M	0.06%	95
2019 Q2	$4.56M	Buy	70,661 +15,006	+27%	+$968K	0.12%	74
2019 Q1	$3.53M	Buy	+55,655	New	+$2.92M	0.11%	80

Other funds holding TNDM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Axiom Investors's TNDM Position: Q4 2019 in Review

Axiom Investors sold out of Tandem Diabetes Care (TNDM) in Q4 2019, closing a stake of 37,440 shares — an estimated $2.21M sold.

Axiom Investors first reported a position in TNDM in Q1 2019 and held it in 3 quarters. The position peaked at $4.56M in Q2 2019. 284 funds tracked by Wall St. Rank hold TNDM as of Q4 2019.

Axiom Investors reported no remaining Tandem Diabetes Care position as of Q4 2019 after selling out during the quarter.
Axiom Investors sold 37,440 Tandem Diabetes Care shares in Q4 2019, an estimated $2.21M.
Axiom Investors first reported a position in Tandem Diabetes Care in Q1 2019 and held it in 3 quarters.
Axiom Investors's Tandem Diabetes Care position peaked at $4.56M in Q2 2019.
284 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2019.

Based on Axiom Investors's 13F filing for Q4 2019, filed 13 Feb 2020.